Factor Xa inhibitors - equivalent to low molecular weight heparin for the treatment of cancer-associated venous thromboembolism].

Venous thromboembolism (VTE) is a common cause of morbidity and mortality in cancer patients. Cancer-associated VTE has an increased risk of recurrence and often cancer confers an increased risk of bleeding, which complicates treatment with anticoagulation. Traditionally, patients with cancer-associated VTE was treated with low molecular weight heparin (LMH). In total, 4 randomized controlled trials have compared non-vitamin K antagonist oral anticoagulantia (NOAC) with LMH. The NOACs studied are the factor Xa inhibitors apixaban, edoxaban, and rivaroxaban. A metaanalysis of these 4 trials have shown at least similar efficacy for prevention of new VTE and a similar risk of bleeding.

Citation

Peter Magnusson, Gustav Mattsson. Factor Xa inhibitors - equivalent to low molecular weight heparin for the treatment of cancer-associated venous thromboembolism]. Lakartidningen. 2021 Apr 08;118

Mesh Tags

Substances

PMID: 33836092

search → result